NEW YORK (GenomeWeb) – Meridian Bioscience today reported a slight improvement in its fiscal third quarter sales as it missed consensus Wall Street expectations on the top and bottom lines.

The Cincinnati-based firm said that for the three months ended June 30, sales inched up to $47.2 million, an increase of a fraction of 1 percent from $47.1 million during its fiscal year 2013 third quarter and below the average analyst estimate of $48 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.